AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Structure Therapeutics Statistics
Share Statistics
Structure Therapeutics has 57.25M shares outstanding. The number of shares has increased by 23.37% in one year.
Shares Outstanding | 57.25M |
Shares Change (YoY) | n/a |
Shares Change (QoQ) | 3.79% |
Owned by Institutions (%) | n/a |
Shares Floating | 54.18M |
Failed to Deliver (FTD) Shares | 24.83K |
FTD / Avg. Volume | 2.96% |
Short Selling Information
The latest short interest is 10.44M, so 18.24% of the outstanding shares have been sold short.
Short Interest | 10.44M |
Short % of Shares Out | 18.24% |
Short % of Float | 19.28% |
Short Ratio (days to cover) | 15.69 |
Valuation Ratios
The PE ratio is -16.71 and the forward PE ratio is -48.01.
PE Ratio | -16.71 |
Forward PE | -48.01 |
PS Ratio | 0 |
Forward PS | null |
PB Ratio | 3.31 |
P/FCF Ratio | -18.34 |
PEG Ratio | n/a |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Structure Therapeutics Inc..
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 19.14, with a Debt / Equity ratio of 0.
Current Ratio | 19.14 |
Quick Ratio | 19.14 |
Debt / Equity | 0 |
Total Debt / Capitalization | 0 |
Cash Flow / Debt | 0 |
Interest Coverage | -7.67 |
Financial Efficiency
Return on equity (ROE) is -0.2% and return on capital (ROIC) is -22.48%.
Return on Equity (ROE) | -0.2% |
Return on Assets (ROA) | -0.19% |
Return on Capital (ROIC) | -22.48% |
Revenue Per Employee | 0 |
Profits Per Employee | -658.97K |
Employee Count | 136 |
Asset Turnover | 0 |
Inventory Turnover | 0 |
Taxes
Income Tax | 236.00K |
Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -43.48% in the last 52 weeks. The beta is -5.13, so Structure Therapeutics 's price volatility has been lower than the market average.
Beta | -5.13 |
52-Week Price Change | -43.48% |
50-Day Moving Average | 32.36 |
200-Day Moving Average | 37.94 |
Relative Strength Index (RSI) | 34.13 |
Average Volume (20 Days) | 838.43K |
Income Statement
Revenue | n/a |
Gross Profit | -949.17K |
Operating Income | -102.78M |
Net Income | -89.62M |
EBITDA | -102.46M |
EBIT | n/a |
Earnings Per Share (EPS) | -2.44 |
Balance Sheet
The company has 129.79M in cash and 5.45M in debt, giving a net cash position of 124.34M.
Cash & Cash Equivalents | 129.79M |
Total Debt | 5.45M |
Net Cash | 124.34M |
Retained Earnings | -206.57M |
Total Assets | 933.22M |
Working Capital | 890.22M |
Cash Flow
In the last 12 months, operating cash flow was -79.49M and capital expenditures -2.17M, giving a free cash flow of -81.66M.
Operating Cash Flow | -79.49M |
Capital Expenditures | -2.17M |
Free Cash Flow | -81.66M |
FCF Per Share | -2.22 |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
GPCR does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | -9.63% |
FCF Yield | -5.63% |
Analyst Forecast
The average price target for GPCR is $80, which is 215.7% higher than the current price. The consensus rating is "Buy".
Price Target | $80 |
Price Target Difference | 215.7% |
Analyst Consensus | Buy |
Analyst Count | 7 |
Scores
Altman Z-Score | 26.14 |
Piotroski F-Score | 3 |